Usefulness of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) in patients for unresectable biliary carcinoma

Yuji Morine, Mitsuo Shimada, Torn Ikegami, Satoru Imura, Hirohumi Kanemura, Yusuke Arakawa, Jun Hanaoka, Mami Kanamoto, Akira Nii

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)


Background/Aii Advanced biliary carcinoma have poor prognosis and chemotherapy has been shown to have little imapact The aim of the present study is to clarify the effectiveness of GEM combined with CDDP and 5FU (GFP) therapy for unre-sectahtebStarYcansaoma. Meihodologyi Fourteen patients with biliary carcinoma (4 patients; gaSbkdder cancer, 10 patients; biliary tract) who had no prior chemotherapy were enrolled. A triple combination of agents was administered with a 4-week cycle GP chemotherapy consisting of GEM at l000ingIm2 on days 1 and of 5-FU 250mg1m2 and CDDP at 3mgIm2 on days 1 to 5. Results: No patient achieved CR, while five patients achieved PR as assessed by RECIST. The overall response rate from the intent-to-treat analysis was 21.4%. Stable disease was observed in 9 (64.3%) patients. Clinical benefit rate was observed in 14 (85.7%) patients. According to the tumor site, overall response rate waa 20.0% in biliary tract car-cktoma. Conclusions: The significant antitumor activity of GFP chemotherapy has been seen in patients with advanced biliary carcinoma. However, further evaluation in large numbers of patients is needed to determine the difference in chemosensitivity according to the tumor site.

Original languageEnglish
Pages (from-to)307-312
Number of pages6
Issue number90
Publication statusPublished - Mar 2009
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'Usefulness of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) in patients for unresectable biliary carcinoma'. Together they form a unique fingerprint.

Cite this